Drug intelligence / Profile preview

Tegafur + Epirubicin + Fluorouracil

Development stage: Unknown
Lead developer: Taiho Pharmaceutical
Modality: DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
Administration: Oral, Intravenous

Overview

This combination involves three anticancer drugs: - **Tegafur** is a prodrug of fluorouracil, which acts as an antimetabolite interfering with DNA synthesis. - **Epirubicin** is an anthracycline antibiotic that intercalates DNA strands, preventing cell replication. - **Fluorouracil** is a pyrimidine analog that inhibits thymidylate synthase, disrupting DNA synthesis. The combination is not a standard formulation but could be used in cancer treatments, potentially including gastric or breast cancer.

Targets

TS (Thymidylate synthase)DNA

Beyond the preview

Go deeper on Tegafur + Epirubicin + Fluorouracil.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tegafur + Epirubicin + Fluorouracil.

Explore the full profile